Table 2.
Compliance with treatment stratified according to different variables
| Compliance | 95 % CI para % | ||||
|---|---|---|---|---|---|
| Variable | N | n | (%) | (lower-upper) | p value |
| Global | 3684 | 816 | (22.1) | (20.8–23.5) | |
| Gender | |||||
| Male | 988 | 211 | (21.4) | (18.7–24.0) | 0.483 |
| Female | 2696 | 605 | (22.4) | (20.8–24.0) | |
| Age group | |||||
| Under 35 | 582 | 85 | (14.6) | (11.7–17.5) | <0.001(*) |
| 35–64 | 1901 | 411 | (21.6) | (19.7–23.5) | |
| Over 65 | 1201 | 320 | (26.6) | (24.1–29.2) | |
| Polypharmacy | |||||
| =<2 | 826 | 59 | (7.1) | (5.4–8.9) | <0.001(*) |
| 2–2.6 | 822 | 123 | (15.0) | (12.5–17.5) | |
| 2.7–4.3 | 1057 | 276 | (26.1) | (23.4–28.8) | |
| >4.3 | 979 | 358 | (36.6) | (33.5–39.6) | |
| Diagnosis recorded | |||||
| None | 1785 | 351 | (19.7) | (17.8–21.5) | <0.001(*) |
| Only anxiety | 923 | 194 | (21.0) | (18.3–23.7) | |
| Only depression | 704 | 197 | (28.0) | (24.6–31.4) | |
| Both | 272 | 74 | (27.2) | (21.8–32.6) | |
| Drug dispenseda | |||||
| Amitriptyline | 787 | 167 | (21.2) | (18.3–24.1) | 0.479 |
| Paroxetine | 1880 | 332 | (17.7) | (15.9–19.4) | <0.001(*) |
| Fluoxetine | 1324 | 323 | (24.4) | (22.0–26.8) | 0.014(*) |
| Citalopram | 1363 | 318 | (23.3) | (21.0–25.6) | 0.186 |
| Sertraline | 1024 | 266 | (26.0) | (23.2–28.7) | 0.001(*) |
| Venlafaxine | 932 | 309 | (33.2) | (30.1–36.2) | <0.001(*) |
| Clomipramine | 414 | 142 | (34.3) | (29.6–39.0) | <0.001(*) |
| Mirtazapine | 492 | 153 | (31.1) | (26.9–35.3) | <0.001(*) |
| Trazodone | 230 | 45 | (19.6) | (14.3–24.8) | 0.33 |
| Maprotiline | 122 | 44 | (36.1) | (27.4–44.8) | <0.001(*) |
| Imipramine | 42 | 16 | (38.1) | (23.1–53.1) | 0.012(*) |
| Nortriptyline | 25 | 10 | (40.0) | (20.4–59.6) | 0.031(*) |
| Fluvoxamine | 118 | 39 | (33.1) | (24.4–41.7) | 0.004(*) |
*Significance using chi-squared test: p-value <0.05
aSome of the active principles were not considered because patient numbers were insufficient